REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
333.34
-9.63 (-2.81%)
At close: 4:00PM EDT

333.34 0.00 (0.00%)
After hours: 4:58PM EDT

Stock chart is not supported by your current browser
Previous Close342.97
Open346.40
Bid333.02 x 800
Ask333.18 x 800
Day's Range332.23 - 347.49
52 Week Range281.89 - 442.00
Volume1,838,558
Avg. Volume719,988
Market Cap36.269B
Beta (3Y Monthly)1.13
PE Ratio (TTM)15.66
EPS (TTM)21.29
Earnings DateMay 7, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est430.19
Trade prices are not sourced from all markets
  • Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran
    Zacks2 days ago

    Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

    Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on the same.

  • Calculating The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
    Simply Wall St.2 days ago

    Calculating The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

    How far off is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and disco...

  • Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA
    Zacks2 days ago

    Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA

    The FDA accepts Novartis' (NVS) BLA seeking approval for brolucizumab for the treatment of wet AMD.

  • Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran
    Zacks3 days ago

    Alnylam (ALNY) Reports Phase III ENVISION Data on Givosiran

    Alnylam (ALNY) reports complete positive results from the phase III ENVISION study of givosiran for the treatment of acute hepatic porphyria.

  • TheStreet.com3 days ago

    Stalking an Entry in Regeneron Pharmaceuticals

    It's because we can make a case for a bigger-picture bullish trend with a different pattern of higher highs and lows. What's most important in my opinion, is whether you have a setup for a market entry.

  • 4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics
    Zacks7 days ago

    4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

    We take a look at companies, which have been developing treatments for various diseases using RNAi technology.

  • Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More
    Zacks8 days ago

    Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

    Key highlights of the past week are new drug approvals, collaborations and pipeline updates.

  • Markit9 days ago

    See what the IHS Markit Score report has to say about Regeneron Pharmaceuticals Inc.

    Regeneron Pharmaceuticals Inc NASDAQ/NGS:REGNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for REGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting REGN. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding REGN is favorable, with net inflows of $140.23 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics
    Zacks9 days ago

    Regeneron, Alnylam Extend Collaboration for RNAi Therapeutics

    Regeneron (REGN) extends collaboration agreement with Alnylam to develop new RNAi therapeutics for diseases of the eye and central nervous system (CNS).

  • PR Newswire10 days ago

    Regeneron to Report First Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2019

    TARRYTOWN, N.Y. , April 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its first quarter 2019 financial and operating results on Tuesday, May ...

  • Benzinga10 days ago

    Regeneron, Alnylam Strike $1B Collaboration For RNAi-based Therapeutics

    In a biotech tie-up, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a collaboration agreement Monday with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY). Regeneron and Alnylam said they will exclusively collaborate on discovering, developing and commercializing new RNA interface — or RNAi — therapeutics for a broad range of disease targets expressed in the eye and central nervous system. The companies will also work on therapies for a select number of targets expressed in the liver. The agreement has Regeneron paying $400 million upfront to Alnylam and buying up to $400 million worth of Alnylam stock at $90 per share.

  • Reuters10 days ago

    Regeneron forays into gene-silencing therapies with Alnylam tie-up

    Regeneron Pharmaceuticals Inc said it would invest $800 million in Alnylam Pharmaceuticals Inc to develop treatments for eye and central nervous system diseases using gene-silencing RNA interference (RNAi) technology. Alnylam, which last year won U.S. approval for the first treatment using the Nobel prize-winning technology, has a host of other such therapies in its pipeline for various genetic, cardio-metabolic, liver and eye and central nervous system (CNS) diseases. Regeneron will make a $400 million upfront payment to Alnylam and also purchase 4.44 million of Alnylam common shares at $90 per share.

  • Alnylam trades partner Sanofi for Regeneron in $800M deal
    American City Business Journals10 days ago

    Alnylam trades partner Sanofi for Regeneron in $800M deal

    Cambridge gene therapy firm Alnylam is changing alliances, cutting research ties with longtime partner Sanofi and teaming up with Regeneron on new eye and central nervous system treatments.

  • Business Wire10 days ago

    Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, and Regeneron Pharmaceuticals, Inc. (REGN), announced today a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases. Regeneron will lead development and commercialization for all programs targeting eye diseases, with Alnylam entitled to potential milestone and royalty payments.

  • PR Newswire10 days ago

    Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases

    Regeneron Pharmaceuticals, Inc. (REGN) and Alnylam Pharmaceuticals, Inc. (ALNY) today announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies' scientific and technological expertise and will build on Alnylam's recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS. Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases.

  • Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up
    Zacks14 days ago

    Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up

    Inovio's (INO) investigational HPV therapy, INO-3106, achieves the clinical efficacy for treating patients with recurrent respiratory papillomatosis, an HPV-associated disease. Shares up.

  • Allergan's AMD Drug Lowers Inflammation in Phase III Study
    Zacks15 days ago

    Allergan's AMD Drug Lowers Inflammation in Phase III Study

    Allergan's (AGN) MAPLE study evaluating a 12-week dose of abicipar pegol demonstrates decreased intraocular inflammation in nAMD patients.

  • Inovio Closes Enrollment in Brain Cancer Study Before Time
    Zacks16 days ago

    Inovio Closes Enrollment in Brain Cancer Study Before Time

    Inovio (INO) concludes enrollment in the phase I/II study on INO-5401+INO-9012 combined with Regeneron/Sanofi's Libtayo for the newly-diagnosed subjects with glioblastoma prior to the scheduled date.

  • Analysts Raise Their Target Price for Regeneron in March
    Market Realist20 days ago

    Analysts Raise Their Target Price for Regeneron in March

    Analysts Are Feeling Good about These Biotech Stocks in MarchAnalysts’ recommendations and target priceWall Street analysts expect a potential upside of 6.79% for Regeneron Pharmaceuticals (REGN) based on the company’s closing price on March 27.

  • Is Regeneron Pharmaceuticals Inc (REGN) A Good Stock To Buy?
    Insider Monkey21 days ago

    Is Regeneron Pharmaceuticals Inc (REGN) A Good Stock To Buy?

    The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the fourth quarter, which unveil their equity positions as of December 31. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]

  • Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Financial Strength Analysis
    Simply Wall St.22 days ago

    Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN): Financial Strength Analysis

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Investors looking for stocks with high market liquidity and little debt on the balance sheet should consider Regeneron Phar...

  • Peninsula biotech lines up chance to crack the peanut allergy nut
    American City Business Journals24 days ago

    Peninsula biotech lines up chance to crack the peanut allergy nut

    The Brisbane company next year could have FDA and European approvals for a way to protect people with peanut allergy from accidental exposures. But competitors are numerous.

  • GlobeNewswire24 days ago

    Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals
    Motley Fool25 days ago

    Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals

    Which stock wins in a battle between these two successful biotechs?

  • Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial
    Yahoo Finance28 days ago

    Biogen shares tank nearly 30% after pulling key Alzheimer’s drug trial

    Biotech giant Biogen stock cratered 28% on Thursday, after the company announced that it would be pulling the plug on its ate-stage trial of its Alzeimer’s drug aducanumab.